NCT00434317已完成4 期
A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Measurement of pain assessed by a Visual Analogue Scale (VAS)
研究概览
简要总结
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
ZOL446
Experimental
干预措施: Zoledronic acid (Drug)
结局指标
主要结局
Measurement of pain assessed by a Visual Analogue Scale (VAS)
时间窗: throughout the study
次要结局
- Quality of Life assessment at baseline and last visit(throughout the study)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
4 期
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.Multiple MyelomaNCT00242528Novartis
终止
3 期
Maintaining Bone Strength in Men With Prostate CancerProstate CancerNCT00391950Novartis300
终止
3 期
Zoledronic Acid in MS-patients With OsteoporosisMultiple SclerosisOsteoporosisNCT01166178Novartis29
已完成
3 期
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation PeriodPaget's Disease of BoneNCT00051636Novartis Pharmaceuticals172
已完成
4 期
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer PatientsFirst or Second Line HER2-negative Breast CancerMetastatic Disease Without Bone MetastasisNCT01129336Novartis Pharmaceuticals44